Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2020 Aug;34(8):2125-2137.
doi: 10.1038/s41375-020-0915-9. Epub 2020 Jun 22.

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Andreas Hochhaus  1 , Carlo Gambacorti-Passerini  2 , Camille Abboud  3 , Bjørn Tore Gjertsen  4 , Tim H Brümmendorf  5 , B Douglas Smith  6 , Thomas Ernst  7 , Pilar Giraldo-Castellano  8 , Ulla Olsson-Strömberg  9 , Susanne Saussele  10 , Nathalie Bardy-Bouxin  11 , Andrea Viqueira  12 , Eric Leip  13 , T Alexander Russell-Smith  14 , Jocelyn Leone  13 , Gianantonio Rosti  15 , Justin Watts  16 , Francis J Giles  17 ; BYOND Study Investigators
Collaborators, Affiliations
Clinical Trial

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Andreas Hochhaus et al. Leukemia. 2020 Aug.

Abstract

Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-negative/BCR-ABL1+ CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 year after last enrolled patient (median treatment duration 23.7 months), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 year was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major molecular response (MMR) rates by 1 year were 80.6% and 70.5%, respectively, in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 year and MMR by 1 year, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs.

PubMed Disclaimer

Conflict of interest statement

Authors declare the following potential conflicts of interest: AH received honoraria from BMS, Novartis, Pfizer, and Takeda, and received research support from BMS, Incyte, Novartis, and Pfizer. CGP provides consultancy to BMS and received honoraria and research support from Pfizer. CA serves on the advisory board for Archer DX, Jazz Pharma, and Tetraphase Pharma, provides consultancy to Actinium, Agios, Bayer, Cardinal Health, Gerson Lehman Group, Incyte, Jazz Pharma, NKarta, Pfizer, Seattle Genetics, and Tetraphase Pharma, received honoraria from Agios, Cardinal Health, and Jazz Pharma, received research support from Pfizer, and serves on the speakers bureau for Jazz Pharma / provides expert testimony for Dava Oncology. BTG is a consultant for BerGenBio, Novartis, Pfizer, and Sanofi Genzyme, received research support from Pfizer, and has stock ownership in Alden Cancer Therapy AS and KinN Therapeutics AS. THB is a consultant for Janssen, Merck, Novartis, Pfizer, and Takeda, and received research support from Novartis and Pfizer. BDS received honoraria for consulting to Agios, Celgene, Jazz Pharma, Novartis and Pfizer, and received research support from Pfizer. PGC received research support from BMS and Pfizer. UOS received research support from Pfizer. SS received honoraria from BMS, Incyte, Novartis, and Pfizer, and received research support from BMS, Incyte, Novartis, and Pfizer. TE received research support from BMS, Incyte, Novartis, and Pfizer. NBB, AV, EL, ARS and JL are employees of Pfizer. GR received research support from Pfizer and served on the speaker bureau for BMS, Incyte, Novartis, and Pfizer. JW serves on the advisory board for Jazz Pharma and Takeda, received research support from Pfizer and Takeda, and serves on the data monitoring committee for Rafael Pharma. FJG is a consultant to Actuate Therapeutics Inc, provides expert testimony to Novartis, and received research support from Pfizer.

Figures

Fig. 1
Fig. 1. Patient disposition.
Full analysis set. The 14 participants screened but not enrolled did not meet the eligibility criteria. AE adverse events, AP accelerated phase, CML chronic myeloid leukemia, CP chronic phase, FAS full analysis set, Ph Philadelphia chromosome.
Fig. 2
Fig. 2. Cumulative Incidence of Molecular Response in Patients with Ph+ CP CML.
(a) MMR, (b) MR4, and (c) MR4.5. CML chronic myeloid leukemia, CP chronic phase, MMR major molecular response, MR molecular response, Ph Philadelphia chromosome.
Fig. 3
Fig. 3. Observed mean (SE) FACT-Leu values over 12 months of bosutinib treatment.
CML chronic myeloid leukemia, CP chronic phase, CP2L second-line, CP3L third-line, CP4L fourth-line, FACT-Leu functional assessment of cancer therapy–leukemia, Ph Philadelphia chromosome, SE Standard error.
See this image and copyright information in PMC

References

    1. National Cancer Institute. Chronic Myelogenous Leukemia Treatment (PDQ®). 2020. https://www.cancer.gov/types/leukemia/hp/cml-treatment-pdq#_1
    1. O’Brien SG, Deininger MW. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Semin Hematol. 2003;40:26–30. doi: 10.1053/shem.2003.50058. - DOI - PubMed
    1. O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl J Med. 2003;348:994–1004. doi: 10.1056/NEJMoa022457. - DOI - PubMed
    1. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl J Med. 2010;362:2260–70. doi: 10.1056/NEJMoa1002315. - DOI - PubMed
    1. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251–9. doi: 10.1056/NEJMoa0912614. - DOI - PubMed

Publication types

MeSH terms

Associated data